Johnson & Johnson acquires Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.

Mar 9, 2024 - 18:00

Johnson & Johnson acquires Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has concluded the acquisition of Ambrx Biopharma in a transaction valued at approximately $2bn.

Read the original article

Tags:

Previous Article

SK bioscience to expand vaccine manufacturing plant in South Korea

FDA approves BMS’ Opdivo for urothelial carcinoma

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

BeiGene secures accelerated FDA approval for follicular lymphoma treatment

BeiGene secures accelerated FDA approval for follicular...

Mar 9, 2024

With Ozempic, Wall Street moves on from a whole other class of medicines

With Ozempic, Wall Street moves on from a whole other c...

Oct 12, 2023

STAT Virtual Event | Cancer’s Breakthrough Engine

STAT Virtual Event | Cancer’s Breakthrough Engine

Dec 19, 2023